Amphastar Pharmaceuticals (AMPH) Revenue (2013 - 2026)

Amphastar Pharmaceuticals' Revenue history runs 14 years deep, the most recent figure standing at $171.2 million for Q1 2026.

• In Q1 2026, Revenue changed 0.38% year-over-year to $171.2 million; the TTM figure through Mar 2026 stood at $720.5 million (down 1.39% YoY), while the FY2025 annual figure was $719.9 million, down 1.65% from the prior year.
• Revenue was $171.2 million for Q1 2026 at Amphastar Pharmaceuticals, down from $183.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $191.8 million in Q3 2025 to a low of $120.1 million in Q3 2022.
• Historically, Revenue has averaged $162.7 million across 5 years, with a median of $171.8 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Revenue soared 50.3% in 2023, then decreased 4.38% in 2025.
• A 5-year view of Revenue shows it stood at $135.0 million in 2022, then soared by 31.91% to $178.1 million in 2023, then increased by 4.73% to $186.5 million in 2024, then decreased by 1.83% to $183.1 million in 2025, then retreated by 6.52% to $171.2 million in 2026.
• The last three Revenue figures came in at $171.2 million (Q1 2026), $183.1 million (Q4 2025), and $191.8 million (Q3 2025), per Business Quant data.